Business Wire

PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive procedure now complete, with trial focus s


Titan Medical Reports Second Quarter 2021 Financial Results

Achievement of milestone and receipt of $10 million license payment from Medtronic Augmented Board of Directors and strengthened leadership team Progress on development activities to support submission of IDE application to FDA TORONTO--(BUSINESS WIRE)